Medical education review — 10 November 2026. Not a substitute for individualized diagnosis, prescribing advice or local guidance.
Overview
The hypothalamic-pituitary system coordinates growth, reproduction, water balance, thyroid function and adrenal responses through feedback-regulated neuroendocrine axes. Clinically useful medicines include analogues of GnRH, somatostatin, vasopressin and growth hormone, along with dopamine agonists and hormone-receptor blockers [1, 2].
Physiological classification
Hypothalamic releasing hormones include CRH, TRH, GnRH and GHRH; inhibitory control includes somatostatin and dopamine (the principal prolactin-inhibiting factor). Anterior pituitary hormones are GH, prolactin, ACTH, TSH, LH and FSH. Vasopressin and oxytocin are synthesized in hypothalamic nuclei and transported to the posterior pituitary for release [1].
Drug classes and structures
- GnRH agonists: leuprolide, goserelin and triptorelin cause initial gonadotropin stimulation followed by receptor downregulation with continuous administration.
- GnRH antagonists: degarelix and relugolix suppress LH/FSH without initial agonist flare.
- Somatostatin analogues: octreotide and lanreotide suppress GH and other peptide secretion; octreotide is an octapeptide, not a 14-amino-acid drug.
- Dopamine agonists: cabergoline and bromocriptine activate D2 receptors to suppress prolactin.
- Growth hormone: somatropin is recombinant GH; growth hormone-receptor antagonism can be achieved with pegvisomant.
- Vasopressin analogue: desmopressin is a modified vasopressin nonapeptide (1-deamino-8-D-arginine vasopressin), with predominant V2 activity.
Clinical applications
GnRH analogues are used in prostate cancer, endometriosis, selected fertility protocols and precocious puberty. Dopamine agonists commonly treat prolactinomas. Somatostatin analogues and pegvisomant have roles in acromegaly; treatment is guided by tumor features, IGF-1, comorbidities and specialist recommendations. Somatropin treats documented GH deficiency and selected pediatric growth indications, not routine anti-aging [1, 2].
Desmopressin and posterior pituitary
Desmopressin replaces deficient AVP action in central diabetes insipidus (now often called arginine-vasopressin deficiency) and is used for some bleeding disorders under indication-specific protocols. It increases renal collecting-duct water reabsorption via V2 receptors and aquaporin-2. Excess desmopressin plus unrestricted fluid intake can cause dangerous water retention and hyponatremia; monitor serum sodium, urine output and thirst as appropriate. It is not a uterotonic [1].
Safety and pharmacokinetics
GnRH agonists may cause initial hormone flare, hot flushes and bone loss; antagonists avoid flare but still cause hypogonadal effects. Somatostatin analogues can cause gastrointestinal symptoms, gallstones and glucose abnormalities. Cabergoline may cause nausea, postural hypotension and impulse-control problems; long-term high cumulative exposure requires attention to valvular safety. Somatropin can cause edema, arthralgia and insulin resistance. Choice and monitoring should remain syndrome-specific [1, 2].
Choosing a treatment target
In central adrenal insufficiency, hydrocortisone replaces the missing downstream cortisol signal. Patients need education on stress dosing and emergency glucocorticoid use. In central hypothyroidism, levothyroxine replaces thyroid hormone. Assess adrenal reserve first and provide glucocorticoid coverage when indicated before starting levothyroxine. Follow free T4, since TSH can appear normal despite inadequate thyroid hormone. [3]
For persistent acromegaly after pituitary surgery, octreotide and lanreotide can reduce growth hormone secretion through somatostatin receptors. Pegvisomant blocks growth hormone action at its receptor and reduces IGF-1 production. Measure IGF-1 to assess its biochemical effect. Follow tumour size separately with pituitary imaging. A favourable biochemical result alone cannot establish that the tumour has shrunk. [4, 5]
Oxytocin stimulates uterine smooth muscle. During intravenous induction or augmentation of labour, monitor contractions and fetal heart rate and titrate the infusion to response. Excessive uterine activity can compromise fetal oxygenation and requires prompt interruption of the infusion and obstetric assessment. Its postpartum use to control uterine bleeding involves a different indication and regimen. [6]
Clinical perspective
Do not conflate anterior pituitary hormones with hypothalamic releasing peptides, or oxytocin’s uterotonic action with desmopressin’s kidney-selective antidiuresis.
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. Available from: https://www.endocrine.org/clinical-practice-guidelines/acromegaly
- Endocrine Society. Hormonal replacement in hypopituitarism in adults. Clinical practice guideline. 2016. [cited 2026 Nov 10]. View source.
- Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol. doi:10.1038/s41574-025-01148-2. [cited 2026 Nov 10]. View source.
- Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951. [cited 2026 Nov 10]. View source.
- US Food and Drug Administration. Pitocin (oxytocin injection). Prescribing information. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.